Broadcast Date: 
  • Time: 

Recently investigators have begun to harness new technology such as microfluidic modulation spectroscopy (MMS) to reveal protein structural changes, as a solid understanding of structure and function is extremely important to the effectiveness of biotherapeutic drugs and scientist today are challenged in gathering a complete understanding with current tools. During the biomanufacturing process, proteins such as antibodies, often undergo conformational changes that can alter their secondary structure, leading to critical variations in their overall function. These changes have been historically difficult to detect, as traditional analytical techniques are not great at detecting small differences in protein structure. MMS however, can detect these changes with great sensitivity and accuracy without the need for dilution or chemical alteration. Moreover, MMS offers detailed information on which structural motifs in the protein molecule are changing, providing more guidance to scientists in their efforts to develop more stable antibody molecules and formulations. Join us for this new GEN webinar where we will learn how MMS technology is making a significant impact toward understanding the structures of therapeutic antibodies and antibody drug conjugates.

Presentation Highlights:

  • Characterization of mAb’s and ADC’s without the need for dilutions or concern for your formulation buffer’s excipient interferences, enabled by MMS, is critical to understand the TRUE structure of your drug product at the intended therapeutic conditions.
  • Microfluidic Modulation Spectroscopy provides a reliable platform with increased sensitivity and higher resolution for secondary structure analysis of biotherapeutics.
  • MMS’s Automated walk away workflow makes it applicable for screening studies much earlier in the development process.

Produced with support from:

RedShift Bio Logo


Karan Shah,
Principal Development Associate,

Ioannis Papayannopoulos, Ph.D.
Senior Scientist III,
Celldex Therapeutics

Eugene Ma, Ph.D.
Chief Technical Officer,
RedShift BioAnalytics